Holen Sie sich die Stockscreener-App
0.70
0.36%
0.0025
Handel nachbörslich:
.69
-0.01
-1.43%
Schlusskurs vom Vortag:
$0.6975
Offen:
$0.695
24-Stunden-Volumen:
659.62K
Relative Volume:
0.60
Marktkapitalisierung:
$36.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-81.22M
KGV:
-0.2365
EPS:
-2.96
Netto-Cashflow:
$-74.41M
1W Leistung:
-1.84%
1M Leistung:
+1.67%
6M Leistung:
-21.36%
1J Leistung:
-29.22%
1-Tages-Spanne:
$0.6619
$0.7084
1-Wochen-Bereich:
$0.6619
$0.7535
52-Wochen-Spanne:
$0.62
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Firmenname
Xilio Therapeutics Inc
Sektor
Branche
Telefon
617-833-1027
Adresse
828 WINTER STREET, WALTHAM
Vergleichen Sie XLO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.70 | 36.93M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-16 | Eingeleitet | Guggenheim | Buy |
| 2021-11-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-11-16 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Xilio Therapeutics Inc Aktie (XLO) Neueste Nachrichten
What drives Xilio Therapeutics Inc. stock priceHigh-return market picks - jammulinksnews.com
What analysts say about Xilio Therapeutics Inc. stockConsistently superior profits - jammulinksnews.com
Is Xilio Therapeutics Inc. a good long term investmentOverwhelming profit margins - jammulinksnews.com
What makes Xilio Therapeutics Inc. stock price move sharplyFree Best Stocks to Buy Today - Newser
Xilio Therapeutics Inc. Stock Analysis and ForecastBreakout portfolio performance - Autocar Professional
What analysts say about Xilio Therapeutics Inc. stock outlookFree Step-by-Step Investment Guide - Newser
Why Xilio Therapeutics Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
How Xilio Therapeutics Inc. stock performs during market volatilityFree Deep Market Trend Analysis - Newser
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio Therapeutics Awards $7,400 in Stock Options to Strategic New Employees - Stock Titan
Xilio Therapeutics Executives Increase Holdings - TradingView
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World
Xilio Therapeutics Expands Authorized Shares at Annual Meeting - TipRanks
Xilio Therapeutics Appoints Akintunde Bello to Board of Directors - citybiz
Xilio Therapeutics appoints oncology veteran Akintunde Bello to board By Investing.com - Investing.com South Africa
Xilio Therapeutics expands board, elects new director - Investing.com Australia
Xilio Therapeutics expands board, elects new director By Investing.com - Investing.com South Africa
Xilio Therapeutics Expands Board with New Director - TipRanks
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Manila Times
Xilio Therapeutics appoints oncology veteran Akintunde Bello to board - Investing.com
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., To Its Board Of Directors - MarketScreener
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors - Nasdaq
Bristol Myers Squibb Oncology Leader Joins Xilio Board: Key Boost for Novel Cancer Immunotherapy Programs - Stock Titan
Finanzdaten der Xilio Therapeutics Inc-Aktie (XLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):